Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KARIVA vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Prevention of pregnancy,Management of heavy menstrual bleeding (off-label),Treatment of acne (off-label),Treatment of dysmenorrhea (off-label),Endometriosis pain relief (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Terminal elimination half-life is 4.5 hours; in renal impairment (Cr Cl <30 m L/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Hepatic via CYP3A4 for both ethinyl estradiol and levonorgestrel; undergoes conjugation (glucuronidation and sulfation). Ethinyl estradiol also undergoes oxidative metabolism. Levonorgestrel is reduced and conjugated.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
99% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
0.27 L/kg (range 0.2-0.5 L/kg); distribution into total body water and highly perfused tissues.
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Oral: 85-90% (complete absorption; first-pass metabolism reduces systemic availability to ~75% in elderly).
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use with caution and monitor for adverse effects.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in acute hepatic disease or severe hepatic impairment (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), no specific dosage adjustment is established; use with caution and monitor liver function.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (one tablet daily as per 21/7 regimen).
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Not indicated for use after menopause. No specific elderly considerations as the drug is not used in this population.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptive use. Risk increases with age (>35 years) and with number of cigarettes smoked. Women over 35 who smoke should not use Kariva.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., DVT, PE, MI, stroke),Hepatic neoplasia (benign and malignant) reported,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Retinal thrombosis (discontinue if vision loss or proptosis occurs),Depression,Bleeding irregularities (breakthrough bleeding, amenorrhea),Liver function abnormalities (discontinue if jaundice develops),Chloasma (may persist)
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Active liver disease or benign/malignant liver tumors,Severe hypertension,Diabetes with vascular involvement,Migraine with focal aura (especially if over 35 years),Hypersensitivity to any component,Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir ± dasabuvir
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
No specific food interactions; however, grapefruit juice may increase estrogen levels (theoretical). Avoid high-fat meals as they may affect absorption. Consistent intake with food can reduce nausea.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester exposure associated with cardiovascular defects, limb reduction defects, and neural tube defects. Second and third trimester use linked to fetal hepatic adenoma and female pseudohermaphroditism (due to progestogenic activity).
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Excreted into breast milk. M/P ratio not established. Avoid breastfeeding due to potential adverse effects in nursing infants.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended for use in non-pregnant women.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Kariva (desogestrel/ethinyl estradiol) is a monophasic oral contraceptive. It is effective for contraception but also used for acne and menstrual regulation. Breakthrough bleeding is common in first 3 cycles. Counsel on missed pill protocol. Check for contraindications: smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Note that antibiotics (rifampin, griseofulvin) and anticonvulsants may reduce efficacy.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Take one pill daily at the same time, preferably after an evening meal.,If you miss one pill, take it as soon as remembered; if missed two or more, use backup contraception.,Common side effects include nausea, breast tenderness, and spotting; these usually improve after 3 months.,Avoid smoking while taking this medication, especially if over 35 years old.,Inform your doctor before starting any new medications, including antibiotics and herbal supplements.,Kariva may decrease milk supply; not recommended if breastfeeding.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KARIVA vs ESTROSTEP 21, answered by our medical review team.
KARIVA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KARIVA and ESTROSTEP 21 depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KARIVA is: One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KARIVA and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KARIVA is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester exposure associated with cardiovascular defects, limb reduction defects, and neu. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.